CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for up to $10.4 million for developing high productivity Chinese hamster ovary cell lines for manufacturing filovirus monoclonal antibodies for therapeutic use over a 30-month period. The agreement has a base period and two option periods.
